3 January 1970 Vena Caval Obstruction-Jackson RMEDICAIJSHRNAL (Case 4) the obstruction was found at operation to extend along the entire length of the inferior vena cavi as far as the right atrium, but the history and physical signs in this patient in no way differed from those in patients with low occlusions. Another patient (Case 8) was shown by cavography to have total caval occlusion extending to the right atrium but gave an unremarkable history.
The "textbook" symptoms and physical signs are often not present in patients with inferior vena caval obstruction and as a result many cases remain undiagnosed. Only 33% of our patients were diagnosed correctly before phlebography and all had visible dilated superficial abdominal wall collaterals to aid in diagnosis. There is little doubt that if cavography were performed more often in the investigation of the obscure case of unilateral or bilateral leg swelling and in cases of recurrent varicose veins and ulcers, many more cases of chronic caval obstruction would be diagnosed. It is a safe procedure (Farifias, 1947; Lea Thomas and Fletcher, 1967; Fletcher and Lea Thomas, 1968) reduction in obese non-diabetic patients, and conflicting reports have been published (Patel and Stowers, 1964; Bloom, 1968; Faludi et al., 1968; Roginsky and Sandler, 1968; Munro o3t al., 1969) . To try to clarify the position a double-blind cross-over trial with phenformin and placebo has been carried out.
Material and Method
Fifty patients were selected consecutively from new patients attending the obesity clinic at Salford Royal Hospital. They were referred by consultants in the hospital group and in most cases had been treated for obesity with a reducing diet before being referred to the obesity clinic. All the patients in the trial were initially at least 200/,% above average according to standard height-weight tables. Patients needing special treatment such as diuretics were excluded from the trial, as were known diabetics and patients with an abnormal response to a glucose load. Otherwise all new patients were admitted to the trial in strict rotation.
The patients in the trial attended the hospital pharmacy,
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Treatment with Phenformin Hart and Cohen M sDJUiL 23 where they were given phenformin, 50 mg. sustained release capsules twice a day or placebo in a predetermined random order. At the end of three months the treatment was reversed so that patients starting on phenformin were then given placebo and those who had previously been on placebo were given phenformin during the second three months of the trial. In this way all patients were treated with phenformin for three months and placebo for three months. The placebo capsules were identical with the phenformin capsules in appearance, and the patients were not told that there had been any change in treatment. Until the end of the trial the observers did not know which patients had started on phenformin and which on placebo. At the first visit the patients were physically examined and an oral 50-g. glucose load test was carried out. Blood was taken before the glucose load and at one hour and two hours later. Any patient with a blood sugar of more than 120 mg./100 ml. at two hours after the glucose load was excluded from the trial. At the first visit blood was also taken for serum cholesterol. The glucose load test and serum cholesterol were repeated at the end of the first three months of treatment. All patients attended at monthly intervals and were seen by the same doctor and dietitian. They were weighed on each occasion wearing only a standard hospital dressing-gown. A 1,200-calorie diet modified according to his or her own taste was given to each patient, the standard diet sheets being amended by the dietitian. Instructions were standardized so far as possible and an effort was made to use the same degree of emphasis on all occasions, even if the patient had not lost weight. If after the first month there had been no loss in weight the diet was discussed again and it was explained to the patient that if the calorie intake was less than the daily requirements then there would be loss of weight. If at the end of the second month there had been no loss of weight the patient was given a diet planner to record his or her daily intake of food and drink, and this was discussed subsequently with the dietitian. greater than 10'% reduction in their serum cholesterol level after three months had lost weight. Considering the variation in serum cholesterol values noted we were unable to demonstrate any effect of phenformin on reduction of serum cholesterol beyond that accompanying weight reduction. Also not all patients who lost weight showed a reduction in cholesterol levels.
kg. lb. Results Of the 50 patients entering the trial 43 were women and 7 men. Two of the women became pregnant during the trial, three were found to be diabetic, and five defaulted. One of the men also defaulted, leaving 33 women and six men who completed the six-month period.
Weight.-The results are shown in Figs. 1 and 2 . In the first three months 20 patients received phenformin and 19 placebo. The average weight loss during the three-month period was 12-5 lb. (5.7 kg.) for the patients taking phenformin and 11.7 lb. (5-3 kg.) for the patients taking placebo. During the second three-month period 19 patients received phenformin and 20 patients received placebo. The average weight loss 4-7 lb. (2-1 kg.), was the same for-each group. 
Discussion
Phenformin has been shown to produce weight reduction in obese diabetics but its action in non-diabetics is still disputed (Roginsky and Barnet, 1966; Faludi et al., 1968; Roginsky and Sandler, 1968) . Some workers (Munro et al., 1969) have shown it to be of value in promoting weight re--duction, but their results can be questioned on grounds of dosage and side-effects. We have taken the precaution of excluding diabetics by a glucose load test and have given phenformin only in therapeutic dosage. In this way there was less danger that weight reduction could have been due to anorexia produced by the drug or interference with intestinal absorption (Sadow, 1962; Patel and Stowers, 1964; Czyzyk et al., 1968) .
Our results show that obese non-diabetics taking a reducing diet did not benefit from phenformin given in therapeutic dosage. It had no greater influence on weight reduction than a placebo.
It is believed that the actions of phenformin are to increase the peripheral utilization of glucose, increase insulin clearance, and inhibit gluconeogenesis. This has been shown in diabetics but not conclusively in normal subjects (Fajans et al., 1960; Boshell et al., 1968; Butterfield, 1968; Lyngs0e and TrapJensen, 1969) .
Our experience leads to the conclusion that there exists in obese patients with diabetes a metabolic disturbance which is favourably modified by phenformin to effect weight reduction. There are obese non-diabetic patients who do not have this metabolic disorder and therefore do not lose weight as a result of phenformin administration, even though phenformin therapy results in a significant reduction in insulin levels, if raised, in those subjects (Grodsky et al., 1963) . Possibly this is due to the fact that hepatic gluconeogenesis is unimpaired in obese non-diabetics (Kreisberg, 1968; Searle and Cavalieri, 1968) .
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